Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-06-14 Declaration of Voting R…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
(I) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 14, 2024 AND (II) PAYMENT OF FINAL DIVIDEND
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the poll results of their Annual General Meeting (AGM) held on June 14, 2024, and the payment of the final dividend for the year ended December 31, 2023. It includes detailed voting results on various resolutions such as adoption of financial statements, re-election of directors, appointment of auditors, and dividend declaration. The document does not contain the full annual report or financial statements but reports the outcome of the AGM voting and dividend payment details. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length (7769 characters) and content confirm it is not a brief report publication announcement or a full annual report. Therefore, the correct classification is DVA with high confidence.
2024-06-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued shares or treasury shares, including share buybacks and repurchases. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) related to disclosure of share capital changes. The content includes detailed tables of shares repurchased for cancellation, dates, prices, and confirmations of compliance with listing rules. This type of document is a regulatory disclosure about share capital changes, specifically share repurchases and treasury shares transactions. It is not a full financial report, earnings release, or management discussion. It is a formal announcement of share transactions by the company. According to the filing definitions, such documents fall under 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is not a brief announcement but a substantive disclosure of share transactions.
2024-06-13 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued shares or treasury shares, including share buybacks and repurchases. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) related to disclosure of share capital changes. The content includes detailed tables of shares repurchased for cancellation, dates, prices, and confirmation statements about compliance with listing rules and legal requirements. There is no indication of financial statements, earnings data, management discussion, or other report types. The document is a regulatory disclosure about share capital changes, specifically share repurchases and treasury shares transactions. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement of a report. Therefore, the correct classification is POS with high confidence.
2024-06-12 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and repurchases. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) concerning disclosure of share capital changes. The content includes detailed tables of shares repurchased for cancellation, dates, prices, and confirmations of compliance with listing rules. This type of document is a regulatory disclosure about share repurchase activities and changes in capital structure, not a full financial report or earnings release. It fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is not a brief announcement but a substantive disclosure report. Therefore, the correct classification is POS with high confidence.
2024-06-11 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details numerous repurchases of shares with dates, quantities, and prices, confirming compliance with listing rules. The content is a regulatory disclosure about share repurchase activities, not a financial report or earnings release. It fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback of its own shares. The document is substantive and detailed, not merely an announcement or certification, so it is not classified as Regulatory Filings or Report Publication Announcement.
2024-06-07 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return filed by Simcere Pharmaceutical Group Limited, detailing changes in issued share capital and share buybacks. It references compliance with the Main Board Listing Rules and GEM Listing Rules of the Hong Kong Stock Exchange. The content includes detailed data on repurchases of shares, dates, quantities, and prices, confirming that these repurchases were made in accordance with listing rules. This type of document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It fits the definition of a Transaction in Own Shares (POS) filing, which reports the company's buyback activities.
2024-06-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.